REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Skip Baldino was appointed in early March to the role of President and Chief Executive
Gynesonics Announces Publications on Healthcare Economic Analyses Demonstrating Cost Savings
The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of
Gynesonics Receives FDA Clearance to Market Next Generation Sonata System 2.1
EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the
Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress
2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine
Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access
Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive
Gynesonics Announces $75 Million Equity Financing
Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75
Interview with Stamford Health System Chief of Gynecology
Dr. Scott Chudnoff, Chief of Gynecology at Stamford Health System in Stamford, Connecticut, is the lead author of the SONATA Trial 12 month results published in the January 2019 issue of Obstetrics and Gynecology.
Gynesonics Technology to be Featured in Presentations at 2018 AAGL Global Congress
Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 - Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its